FDA Speeds Up Review Of Roche’s Immunotherapy Drug Tecentriq For Bladder Cancer – Counsel & Heal
Counsel & Heal |
FDA Speeds Up Review Of Roche’s Immunotherapy Drug Tecentriq For Bladder Cancer
Counsel & Heal On January 2017, FDA has granted Tecentriq (atezolizumab) as a cancer immunotherapy drug. It has been evaluated as the first-line treatment option for people not eligible for cisplatin chemotherapy. The drug is also intended for people who are either … Roche Gets Priority Review for Immunotherapy Drug TecentriqZacks.com |
News Transcript |
Immunotherapy clinical trial aims to combat brain cancer
News Transcript The study compares immunotherapy that uses a retrovirus designed to selectively infect and kill proliferating cancer cells and stimulate a patient’s own immune system to attack recurring high-grade gliomas – glioblastoma and anaplastic astrocytoma – to … |
The Scientist |
Enhancing Stem Cells Helps Regenerate Damaged Teeth in Mice
The Scientist PIXABAYStem–cell enhancing drugs can successfully promote teeth to repair themselves, at least in mice, according to a study published January 9 in Scientific Reports. When a tooth loses dentin, the boney layer beneath the enamel, stems cells deep in … Natural tooth repair method, using Alzheimer’s drug, could revolutionize dental treatmentsScience Daily Can teeth repair themselves without fillings?CBS News Scientists have found a drug that regenerates teeth, and it could reduce the need for fillingsScienceAlert Medical Daily –Monthly Prescribing Reference (registration) –Genetic Engineering & Biotechnology News all 46 news articles » |
|
Sarepta Therapeutics (SRPT) Licenses Galgt2 Gene Therapy Program from Nationwide Children’s Hospital
StreetInsider.com The experimental program explores the potential surrogate gene therapy approach to Duchenne muscular dystrophy. As a “surrogate gene therapy approach”, the gene therapy looks to induce genes that make proteins that can perform a similar function as … |
Tech Times |
Roche Gets Priority Review for Immunotherapy Drug Tecentriq
Zacks.com Roche Holding AG’s (RHHBY – Free Report) Genentech announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq, for the treatment of patients … FDA To Speed Up Review Of Roche Tecentriq As Immunotherapy Treatment For Bladder CancerTech Times FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ …Business Wire (press release) FDA speeds up review of Roche’s bladder cancer drugEyewitness News News Recorder all 13 news articles » |